(1S,3Z)-3-[(2E)-2-[(3aS,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: (1S,3Z)-3-[(2E)-2-[(3aS,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol
• 化学式: C₂₇H₄₄O₂
• 分子量: 400.6
• InChiKey: JWUBBDSIWDLEOM-MUINDALQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.2
• 重原子数：
  29
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• Insulin vitamin D conjugates
  申请人：Extend Biosciences, Inc.

  公开号：US10420819B2

  公开（公告）日：2019-09-24

  The invention provides non-hormonal vitamin D conjugated to insulin peptides that result in the peptides having increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. The vitamin D targeting groups are coupled to the insulin peptides via the third carbon on the vitamin D backbone.

  本发明提供了与胰岛素肽共轭的非激素类维生素 D，与非共轭形式的胰岛素肽相比，这种维生素 D 可使胰岛素肽的吸收率、生物利用率或循环半衰期增加。维生素 D 靶向基团通过维生素 D 主干上的第三个碳与胰岛素肽结合。
• Therapeutic vitamin D conjugates
  申请人：Extend Biosciences, Inc.

  公开号：US10406202B2

  公开（公告）日：2019-09-10

  The invention provides non-hormonal vitamin D conjugated via the third carbon on the vitamin D backbone to parathyroid hormone (PTH) proteins that result in increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms.

  本发明提供了通过维生素 D 骨架上的第三个碳与甲状旁腺激素（PTH）蛋白共轭的非激素类维生素 D，与非共轭形式相比，这种维生素 D 可提高吸收率、生物利用率或循环半衰期。
• 1-DEOXY ANALOGS OF 1,25-DIHYDROXYVITAMIN D3 COMPOUNDS
  申请人：Posner Gary H.

  公开号：US20130157987A1

  公开（公告）日：2013-06-20

  This present disclosure is directed to novel prodrugs of activated vitamin D3 compounds. The prodrugs can be designed to have one or more beneficial properties, such as selective inhibition of the enzyme CYP24, low calcemic activity, and anti-proliferative activity. Specifically, these prodrugs are 1-deoxy prohormones of active Vitamin D analogs, e.g. analogs of calcitriol. This disclosure is also directed to pharmaceutical and diagnostic compositions containing the prodrugs of the invention, and to their medical use, particularly as prodrugs in the treatment and/or prevention of diseases.
• THERAPEUTIC VITAMIN D CONJUGATES
  申请人：Extend Biosciences, Inc.

  公开号：US20170216449A1

  公开（公告）日：2017-08-03

  The invention provides non-hormonal vitamin D conjugated to apelin proteins that result in increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. In some embodiments, the vitamin D targeting groups are coupled to the apelin proteins via the third carbon on the vitamin D backbone.
• INSULIN VITAMIN D CONJUGATES
  申请人：Extend Biosciences, Inc.

  公开号：US20170252410A1

  公开（公告）日：2017-09-07

  The invention provides non-hormonal vitamin D conjugated to insulin peptides that result in the peptides having increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. The vitamin D targeting groups are coupled to the insulin peptides via the third carbon on the vitamin D backbone.